Differences in growth promotion, drug response and intracellular protein trafficking of FLT۳ mutants
محل انتشار: مجله علوم پایه پزشکی ایران، دوره: 17، شماره: 11
سال انتشار: 1393
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 174
فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IJBMS-17-11_007
تاریخ نمایه سازی: 4 آبان 1400
چکیده مقاله:
Objective(s): Mutant forms FMS-like tyrosine kinase-۳ (FLT۳), are reported in ۲۵% of childhood acute lymphoid leukemia (ALL) and ۳۰% of acute myeloid leukemia (AML) patients. In this study, drug response, growth promoting, and protein trafficking of FLT۳ wild-type was compared with two active mutants (Internal Tandem Duplication (ITD)) and D۸۳۵Y. Materials and Methods:FLT۳ was expressed on factor-dependent cells (FDC-P۱) using retroviral transduction. The inhibitory effects of CEP۷۰۱, imatinib, dasatinib, PKC۴۱۲ and sunitinib were studied on cell proliferation and FLT۳ tyrosine phosphorylation. Total expression and proportion of intracellular and surface FLT۳ was also determined. Results: FDC-P۱ cells became factor-independent after expression of human FLT۳ mutants (ITD and D۸۳۵Y). FDC-P۱ cells expressing FLT۳-ITD grow ۳ to ۴ times faster than those expressing FLT۳-D۸۳۵Y. FD-FLT۳-ITD cells were three times more resistant to sunitinib than the FD-FLT۳-WT cells. The Geo means for surface FLT۳ expression in FD-FLT۳-ITD and –D۸۳۵Y were ۶۵ and ۷۰% less than the FD-FLT۳-WT cells. About ۴۰% of expressed FLT۳ was detected as intracellular in FD-FLT۳-D۸۳۵Y cell compared to ۴ and ۴.۵% in FD-FLT۳-WT and –ITD cells. Conclusion: Retention of D۸۳۵Y FLT۳ mutant protein may cause altered signaling, endoplasmic reticulum stress and activation of apoptotic signaling pathways leading to lower proliferation rate in FD-FLT۳-D۸۳۵Y than the FLT۳-WT and ITD mutant., these may also also contribute, along with the preferential affinity, to the increased sensitivity of D۸۳۵Y of CEP۷۰۱ and PKC۴۱۲. Studying these genetic variations can help determining the prognosis and designing a therapeutic plan for the patients with FLT۳ mutations.
کلیدواژه ها:
نویسندگان
Baratali Mashkani
Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Discipline of Medical Biochemistry, School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW ۲۳۰۸, Australia
Renate Griffith
School of Medical Sciences/Pharmacology, University of New South Wales, Sydney, NSW ۲۰۵۲, Australia School of Environmental and Life Sciences, University of Newcastle, NSW ۲۳۰۸, Australia
Leonie Ashman
Discipline of Medical Biochemistry, School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW ۲۳۰۸, Australia
مراجع و منابع این مقاله:
لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :